Can You Go Back on Mounjaro After a Break?

Does how long you stopped matter for which dose you restart at?

It does, and it's one of the most practical questions people ask when considering a return to treatment. If you paused for only a week or two, your prescriber may be comfortable continuing at the dose you left off. A gap of a month or more is a different picture. The tolerance your digestive system develops while titrating through the lower doses tends to fade when the medicine is absent for an extended period. Reintroducing tirzepatide at a high dose after a significant break increases the likelihood of nausea, vomiting and other gastrointestinal effects returning, sometimes more intensely than when you first started.

For gaps of four weeks or longer, a cautious restart from 2.5mg (the same dose used at the beginning of treatment) is often the approach a prescriber takes, titrating back up at a pace your body can tolerate. For moderate gaps (roughly two to four weeks) the decision is more individual. There's no single universal rule written into the Mounjaro licence; the guidance on restarting is prescriber-led and should be followed closely. The Mounjaro Patient Information Leaflet (available on the electronic Medicines Compendium) is also worth reading for the manufacturer's own advice on missed doses and restarting.

The bottom line: the longer the break, the more likely you are to need a lower re-entry dose, and the slower the upward titration should go.

Will I regain the weight I lost during a break?

This is the question that sits behind most restart enquiries. The honest answer is: for many people, yes, at least some of it. Tirzepatide works partly by reducing appetite and slowing gastric emptying. When you stop, those effects stop with it, and hunger typically returns to something closer to its pre-treatment level. Obesity is a chronic condition with a strong biological component, not a temporary state fixed by a course of treatment, and weight regain after stopping GLP-1 medicines has been reported consistently in clinical studies.

That's not a reason to feel defeated; it's a reason to plan the restart properly. People who notice meaningful regain during a break (or who stopped because of cost or supply, rather than reaching their goal) often find that returning to treatment is entirely appropriate. You can read more about going back on Mounjaro after a break including what to expect in the weeks after restarting.

One practical note: your current weight at the time of restarting is relevant to the prescriber's assessment, not your weight when you originally started. Bring that information to your consultation. It helps.

Are there situations where restarting isn't appropriate?

Mounjaro isn't suitable for everyone, and a break is a sensible moment to reassess. A prescriber will consider whether you still meet the clinical eligibility criteria, broadly, a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for certain ethnic backgrounds under UK clinical guidance. If you've lost significant weight and your BMI has dropped well below these thresholds, continuing may no longer be clinically indicated.

There are also health changes to disclose. If you've been diagnosed with something new since stopping (pancreatitis, certain gallbladder conditions, or other contraindicated conditions listed in the SmPC) that needs to go into the assessment. Pregnancy, breastfeeding and planning a pregnancy are circumstances where tirzepatide is not recommended; a prescriber will ask directly. Under-18s are not within the licensed population for this medicine. If any of these apply, the conversation with a prescriber is exactly the right place to work through what that means for your options.

The full picture on returning to tirzepatide after stopping covers eligibility factors in more detail if you want to read through before a consultation.

How does restarting work in practice through an online pharmacy?

At nume, every restart is treated as a fresh clinical review. There are no auto-renewals. A GPhC-registered Independent Prescriber reads your answers and clinical history the same day, a real clinician, not an automated decision process. If you're transferring back from another provider or from an NHS prescription, you'll be asked to provide evidence of your previous treatment and your most recent dose.

Order before 12pm on a working day and, once your prescriber approves the restart as clinically suitable, treatment is dispatched the same day. It arrives the next working day via DPD in plain, unbranded packaging, a tracked parcel that looks like any other delivery. The pen itself needs to go straight into the fridge door when it arrives, and if you're ever unsure whether a pen that's been stored incorrectly is still usable, our guide on whether tirzepatide goes bad explains what to look for before you inject. For a sense of what the overall cost picture looks like when restarting privately, the Mounjaro price comparison page sets out what's typically included in a private prescription and what to check for. The NHS medicines page for tirzepatide is also a straightforward reference for what the medicine is and how it works, if you'd like a clear clinical overview before restarting.

Ready to pick this back up? Check your eligibility and one of our prescribers will review your situation the same day.